Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 17, 2009

Novartis Signs Four-Year Deal with Horizon for Custom-Generated X-Man Cancer Models

  • Horizon Discovery entered a four-year collaboration with Novartis. The agreement involves the use of Horizon’s Genesis™ gene-engineering platform to develop a broad panel of custom-generated, genetically defined human X-Man cancer models for use by Novartis in its drug discovery programs.

    Horizon will receive up-front, milestone, and renewal fees. The deal is the second between the two companies. In December 2008, Horizon inked a commercial deal with Novartis Institute of Biomedical Research relating to ongoing access to a panel of X-Man cell-lines.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »